Skip to main content
NASDAQ:HCM

Hutchison China MediTech Competitors

$23.70
-1.82 (-7.13 %)
(As of 05/12/2021 04:30 PM ET)
Add
Compare
Today's Range
$23.67
$25.98
50-Day Range
$24.99
$29.99
52-Week Range
$19.77
$37.00
Volume510,077 shs
Average Volume232,252 shs
Market Capitalization$3.53 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.12

Competitors

Hutchison China MediTech (NASDAQ:HCM) Vs. BMRN, ZLAB, GRFS, RDY, TEVA, and JAZZ

Should you be buying HCM stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Hutchison China MediTech, including BioMarin Pharmaceutical (BMRN), Zai Lab (ZLAB), Grifols (GRFS), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), and Jazz Pharmaceuticals (JAZZ).

Hutchison China MediTech (NASDAQ:HCM) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Hutchison China MediTech and BioMarin Pharmaceutical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
BioMarin Pharmaceutical071002.59

Hutchison China MediTech presently has a consensus target price of $40.00, suggesting a potential upside of 68.78%. BioMarin Pharmaceutical has a consensus target price of $118.20, suggesting a potential upside of 56.35%. Given Hutchison China MediTech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Hutchison China MediTech is more favorable than BioMarin Pharmaceutical.

Valuation and Earnings

This table compares Hutchison China MediTech and BioMarin Pharmaceutical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
BioMarin Pharmaceutical$1.70 billion8.11$-23,850,000.00$0.071,080.00

BioMarin Pharmaceutical has higher revenue and earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hutchison China MediTech and BioMarin Pharmaceutical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
BioMarin Pharmaceutical45.74%4.34%2.84%

Risk & Volatility

Hutchison China MediTech has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, BioMarin Pharmaceutical has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 97.7% of BioMarin Pharmaceutical shares are held by institutional investors. 2.2% of BioMarin Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

BioMarin Pharmaceutical beats Hutchison China MediTech on 10 of the 14 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Zai Lab (NASDAQ:ZLAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and price targets for Hutchison China MediTech and Zai Lab, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Zai Lab00503.00

Hutchison China MediTech presently has a consensus target price of $40.00, suggesting a potential upside of 68.78%. Zai Lab has a consensus target price of $197.8460, suggesting a potential upside of 35.43%. Given Hutchison China MediTech's higher possible upside, equities research analysts clearly believe Hutchison China MediTech is more favorable than Zai Lab.

Valuation and Earnings

This table compares Hutchison China MediTech and Zai Lab's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
Zai Lab$12.98 million1,061.81$-195,070,000.00($3.03)-48.04

Hutchison China MediTech has higher revenue and earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Hutchison China MediTech, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Hutchison China MediTech and Zai Lab's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Zai LabN/AN/AN/A

Risk & Volatility

Hutchison China MediTech has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Zai Lab has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 81.3% of Zai Lab shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Hutchison China MediTech beats Zai Lab on 6 of the 9 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Grifols (NASDAQ:GRFS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.

Profitability

This table compares Hutchison China MediTech and Grifols' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Grifols12.79%10.65%4.79%

Risk & Volatility

Hutchison China MediTech has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Grifols has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500.

Valuation and Earnings

This table compares Hutchison China MediTech and Grifols' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
Grifols$5.71 billion2.18$700.16 million$1.1715.49

Grifols has higher revenue and earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 15.2% of Grifols shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and price targets for Hutchison China MediTech and Grifols, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Grifols03502.63

Hutchison China MediTech presently has a consensus target price of $40.00, suggesting a potential upside of 68.78%. Given Hutchison China MediTech's stronger consensus rating and higher possible upside, equities research analysts clearly believe Hutchison China MediTech is more favorable than Grifols.

Summary

Grifols beats Hutchison China MediTech on 8 of the 13 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Dr. Reddy's Laboratories (NYSE:RDY) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Hutchison China MediTech and Dr. Reddy's Laboratories' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Dr. Reddy's Laboratories8.23%16.33%10.79%

Risk and Volatility

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Dr. Reddy's Laboratories has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.

Valuation & Earnings

This table compares Hutchison China MediTech and Dr. Reddy's Laboratories' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
Dr. Reddy's Laboratories$2.32 billion5.13$259 million$2.7925.62

Dr. Reddy's Laboratories has higher revenue and earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 12.9% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hutchison China MediTech and Dr. Reddy's Laboratories, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Dr. Reddy's Laboratories00303.00

Hutchison China MediTech presently has a consensus price target of $40.00, suggesting a potential upside of 68.78%. Dr. Reddy's Laboratories has a consensus price target of $70.00, suggesting a potential downside of 2.06%. Given Hutchison China MediTech's higher probable upside, analysts plainly believe Hutchison China MediTech is more favorable than Dr. Reddy's Laboratories.

Summary

Dr. Reddy's Laboratories beats Hutchison China MediTech on 9 of the 13 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Hutchison China MediTech and Teva Pharmaceutical Industries' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Teva Pharmaceutical Industries-24.17%19.32%4.89%

Risk and Volatility

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hutchison China MediTech and Teva Pharmaceutical Industries' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
Teva Pharmaceutical Industries$16.89 billion0.66$-998,000,000.00$2.314.45

Hutchison China MediTech has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 51.2% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hutchison China MediTech and Teva Pharmaceutical Industries, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Teva Pharmaceutical Industries17302.18

Hutchison China MediTech presently has a consensus price target of $40.00, suggesting a potential upside of 68.78%. Teva Pharmaceutical Industries has a consensus price target of $11.7778, suggesting a potential upside of 14.68%. Given Hutchison China MediTech's stronger consensus rating and higher probable upside, analysts plainly believe Hutchison China MediTech is more favorable than Teva Pharmaceutical Industries.

Summary

Teva Pharmaceutical Industries beats Hutchison China MediTech on 9 of the 14 factors compared between the two stocks.

Hutchison China MediTech (NASDAQ:HCM) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.

Profitability

This table compares Hutchison China MediTech and Jazz Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Hutchison China MediTechN/AN/AN/A
Jazz Pharmaceuticals7.86%20.16%10.85%

Risk and Volatility

Hutchison China MediTech has a beta of 1.12, meaning that its share price is 12% more volatile than the S&P 500. Comparatively, Jazz Pharmaceuticals has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500.

Valuation & Earnings

This table compares Hutchison China MediTech and Jazz Pharmaceuticals' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hutchison China MediTech$204.89 million17.22$-106,020,000.00($0.80)-29.63
Jazz Pharmaceuticals$2.16 billion4.63$523.37 million$14.6012.05

Jazz Pharmaceuticals has higher revenue and earnings than Hutchison China MediTech. Hutchison China MediTech is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

33.5% of Hutchison China MediTech shares are held by institutional investors. Comparatively, 95.7% of Jazz Pharmaceuticals shares are held by institutional investors. 4.6% of Jazz Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Hutchison China MediTech and Jazz Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Hutchison China MediTech00203.00
Jazz Pharmaceuticals111502.82

Hutchison China MediTech presently has a consensus price target of $40.00, suggesting a potential upside of 68.78%. Jazz Pharmaceuticals has a consensus price target of $192.6250, suggesting a potential upside of 9.51%. Given Hutchison China MediTech's stronger consensus rating and higher probable upside, analysts plainly believe Hutchison China MediTech is more favorable than Jazz Pharmaceuticals.

Summary

Jazz Pharmaceuticals beats Hutchison China MediTech on 10 of the 14 factors compared between the two stocks.


Hutchison China MediTech Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
2.1$75.60-0.1%$13.82 billion$1.70 billion17.30Insider Selling
Zai Lab logo
ZLAB
Zai Lab
1.6$145.56-3.1%$13.78 billion$12.98 million-48.04Earnings Announcement
Gap Down
Grifols logo
GRFS
Grifols
1.3$18.12-3.0%$12.83 billion$5.71 billion16.18
Dr. Reddy's Laboratories logo
RDY
Dr. Reddy's Laboratories
1.3$71.47-0.4%$11.93 billion$2.32 billion59.07Upcoming Earnings
Teva Pharmaceutical Industries logo
TEVA
Teva Pharmaceutical Industries
1.6$10.27-0.2%$11.19 billion$16.89 billion-2.79Analyst Report
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
1.9$175.90-1.2%$9.89 billion$2.16 billion55.49Analyst Report
Bausch Health Companies logo
BHC
Bausch Health Companies
1.9$27.92-1.8%$9.83 billion$8.60 billion-5.12
Maravai LifeSciences logo
MRVI
Maravai LifeSciences
1.6$36.18-2.3%$9.11 billionN/A0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Gap Down
United Therapeutics logo
UTHR
United Therapeutics
1.7$195.49-0.6%$8.70 billion$1.45 billion18.49Earnings Announcement
Analyst Report
Mirati Therapeutics logo
MRTX
Mirati Therapeutics
1.6$153.18-1.7%$7.88 billion$3.34 million-19.89Earnings Announcement
Analyst Upgrade
BridgeBio Pharma logo
BBIO
BridgeBio Pharma
2.0$49.48-0.7%$7.33 billion$40.56 million-14.51Earnings Announcement
Arrowhead Pharmaceuticals logo
ARWR
Arrowhead Pharmaceuticals
1.5$68.70-1.6%$7.27 billion$87.99 million-81.79Analyst Revision
Ascendis Pharma A/S logo
ASND
Ascendis Pharma A/S
1.5$136.96-2.4%$7.18 billion$14.98 million-16.68Upcoming Earnings
News Coverage
Ultragenyx Pharmaceutical logo
RARE
Ultragenyx Pharmaceutical
1.7$106.40-2.0%$7.18 billion$103.71 million-24.24Analyst Report
Analyst Revision
GW Pharmaceuticals logo
GWPH
GW Pharmaceuticals
1.3$218.96-0.0%$6.86 billion$311.33 million-127.30
Perrigo logo
PRGO
Perrigo
2.2$45.76-3.1%$5.92 billion$4.84 billion-762.54Earnings Announcement
Unusual Options Activity
News Coverage
Sarepta Therapeutics logo
SRPT
Sarepta Therapeutics
1.9$73.89-3.9%$5.67 billion$380.83 million-9.45Earnings Announcement
Blueprint Medicines logo
BPMC
Blueprint Medicines
1.5$91.65-2.3%$5.47 billion$66.51 million16.91
Allakos logo
ALLK
Allakos
1.7$98.89-0.2%$5.30 billionN/A-36.09Earnings Announcement
News Coverage
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$37.31-1.7%$5.26 billion$1.12 billion77.73Earnings Announcement
Analyst Report
TG Therapeutics logo
TGTX
TG Therapeutics
1.8$36.33-3.3%$5.14 billion$150,000.00-17.14Earnings Announcement
Unusual Options Activity
Galapagos logo
GLPG
Galapagos
1.3$74.14-0.7%$4.82 billion$1.00 billion-11.23Analyst Report
Gap Down
Biohaven Pharmaceutical logo
BHVN
Biohaven Pharmaceutical
2.0$68.27-3.2%$4.37 billionN/A-5.56Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Sage Therapeutics logo
SAGE
Sage Therapeutics
1.4$73.88-0.4%$4.34 billion$6.87 million-7.14Analyst Revision
Schrödinger logo
SDGR
Schrödinger
1.6$59.68-3.5%$4.32 billion$85.54 million0.00Analyst Report
News Coverage
I-Mab logo
IMAB
I-Mab
1.2$62.07-5.3%$4.25 billion$4.31 million-2.15
Agios Pharmaceuticals logo
AGIO
Agios Pharmaceuticals
1.5$54.32-3.4%$3.93 billion$117.91 million-11.02
LEGN
Legend Biotech
1.3$30.35-2.7%$3.93 billion$64.39 million0.00
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$61.23-2.4%$3.80 billion$806.43 million-8.67Analyst Revision
Apellis Pharmaceuticals logo
APLS
Apellis Pharmaceuticals
1.6$46.59-0.1%$3.75 billionN/A-6.28
Alkermes logo
ALKS
Alkermes
1.2$22.44-0.4%$3.60 billion$1.17 billion-48.78
Karuna Therapeutics logo
KRTX
Karuna Therapeutics
1.8$115.68-0.4%$3.39 billionN/A-57.55Earnings Announcement
Analyst Revision
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.5$18.57-3.9%$3.39 billion$114.62 million-7.49Earnings Announcement
Analyst Report
Analyst Revision
ACADIA Pharmaceuticals logo
ACAD
ACADIA Pharmaceuticals
1.9$21.83-4.5%$3.34 billion$339.08 million-12.69Analyst Report
Analyst Revision
Turning Point Therapeutics logo
TPTX
Turning Point Therapeutics
1.7$65.94-1.5%$3.24 billionN/A-18.79Earnings Announcement
Analyst Upgrade
Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.2$58.60-0.3%$3.15 billion$1.11 billion18.84Analyst Report
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.7$37.54-1.1%$3.05 billion$60,000.00-11.66Earnings Announcement
Analyst Revision
Reata Pharmaceuticals logo
RETA
Reata Pharmaceuticals
1.4$81.62-1.8%$3.01 billion$26.52 million-7.19Earnings Announcement
Arvinas logo
ARVN
Arvinas
1.7$63.01-2.7%$3.00 billion$42.98 million-24.61
Insmed logo
INSM
Insmed
1.2$26.46-1.9%$2.79 billion$136.47 million-10.18Earnings Announcement
Analyst Report
Unusual Options Activity
Taro Pharmaceutical Industries logo
TARO
Taro Pharmaceutical Industries
1.1$72.14-0.1%$2.76 billion$644.77 million-10.29Upcoming Earnings
PTC Therapeutics logo
PTCT
PTC Therapeutics
1.3$38.29-1.2%$2.73 billion$306.98 million-5.48
MorphoSys logo
MOR
MorphoSys
0.3$19.95-2.0%$2.68 billion$80.43 million95.00News Coverage
Pacira BioSciences logo
PCRX
Pacira BioSciences
2.3$61.98-2.0%$2.67 billion$421.03 million21.82Analyst Report
News Coverage
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.4$41.61-1.1%$2.57 billionN/A-22.86Earnings Announcement
Gap Up
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.4$58.91-2.1%$2.49 billionN/A0.00
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.22-4.1%$2.45 billion$182.24 million-8.02Earnings Announcement
ALX Oncology logo
ALXO
ALX Oncology
1.9$54.68-10.8%$2.44 billionN/A0.00
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.7$20.61-0.8%$2.39 billion$306.49 million23.16Earnings Announcement
Global Blood Therapeutics logo
GBT
Global Blood Therapeutics
1.8$36.60-3.3%$2.35 billion$2.11 million-7.92Analyst Report
Analyst Revision
This page was last updated on 5/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.